A global approach to <scp>HIV</scp>‐1 vaccine development

Immunological Reviews - Tập 254 Số 1 - Trang 295-304 - 2013
Kathryn E. Stephenson1, Dan H. Barouch1,2
1Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA, USA
2Ragon Institute of MGH, MIT, and Harvard Boston MA USA

Tóm tắt

SummaryA global human immunodeficiency virus‐1 (HIV‐1) vaccine will have to elicit immune responses capable of providing protection against a tremendous diversity of HIV‐1 variants. In this review, we first describe the current state of the HIV‐1 vaccine field, outlining the immune responses that are desired in a global HIV‐1 vaccine. In particular, we emphasize the likely importance of Env‐specific neutralizing and non‐neutralizing antibodies for protection against HIV‐1 acquisition and the likely importance of effector Gag‐specific T lymphocytes for virologic control. We then highlight four strategies for developing a global HIV‐1 vaccine. The first approach is to design specific vaccines for each geographic region that include antigens tailor‐made to match local circulating HIV‐1 strains. The second approach is to design a vaccine that will elicit Env‐specific antibodies capable of broadly neutralizing all HIV‐1 subtypes. The third approach is to design a vaccine that will elicit cellular immune responses that are focused on highly conserved HIV‐1 sequences. The fourth approach is to design a vaccine to elicit highly diverse HIV‐1‐specific responses. Finally, we emphasize the importance of conducting clinical efficacy trials as the only way to determine which strategies will provide optimal protection against HIV‐1 in humans.

Từ khóa


Tài liệu tham khảo

10.1038/nm.2529

10.1146/annurev-med-042010-085643

10.1056/NEJMoa0908492

10.1056/NEJMoa1113425

Bonsignori M, 2012, HIV‐1 antibodies from infection and vaccination: insights for guiding vaccine design, TIM, 20, 532

10.1016/j.coi.2012.04.006

10.1038/nature06106

10.1126/science.1225416

10.1097/QAD.0b013e32835474d2

10.7448/IAS.15.2.17407

10.1038/nature10373

10.1101/cshperspect.a007351

10.1084/jem.20090378

10.1097/QAD.0b013e32835461b5

10.1056/NEJMra0706737

10.1126/science.1070441

10.1385/1-59259-110-8:1

10.1128/JVI.00114-09

Barouch DH, 2009, HIV‐1 vaccine development after Step, Ann Rev Med, 61, 2

10.1097/01.aids.0000247564.73009.bc

10.1093/bmb/58.1.19

Mascola JR, 2010, The role of antibodies in HIV vaccines, Ann Rev Med, 28, 413

10.1146/annurev.med.60.042507.164323

10.1371/journal.pone.0053629

10.1038/nature11519

10.1038/nature10766

10.1126/scitranslmed.3002351

10.1093/infdis/jir199

10.1038/72309

10.1038/5568

10.1128/JVI.73.5.4009-4018.1999

10.1038/72318

10.1371/journal.ppat.1000433

10.1128/JVI.01272-09

10.1128/JVI.75.17.8340-8347.2001

10.1038/nm.1974

10.1073/pnas.1103012108

10.1038/nm833

10.1073/pnas.1214785109

10.1517/14712598.2012.743527

10.1038/nm.2528

10.1128/JVI.01023-12

Liao HX, 2013, Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV‐1 Envelope protein variable regions 1 and 2, Immunity, 12, S1074

10.1128/JVI.01110-12

10.1038/nbt.2197

10.1101/cshperspect.a007252

10.1097/QAD.0b013e328353bcaf

10.1016/j.immuni.2007.08.010

10.1073/pnas.93.23.13125

10.1038/ni1281

10.1097/COH.0b013e3283454c39

10.1371/journal.ppat.1000917

10.1073/pnas.0611244104

10.1128/JVI.00182-09

10.1128/JVI.02028-09

10.1038/nature10003

10.1126/science.283.5403.857

10.1016/j.micinf.2012.05.001

10.1128/JVI.05577-11

10.1126/scitranslmed.3003165

10.1128/JVI.00996-12

10.1073/pnas.1105315108

10.1128/jvi.76.5.2298-2305.2002

10.1128/JVI.02031-09

10.1038/nm1520

10.1128/JVI.00708-07

10.1128/JVI.00315-12

10.1128/JVI.80.6.3122-3125.2006

10.1097/QAD.0b013e3283402206

10.1128/JVI.01103-08

10.1038/nature07469

10.1038/nature11443

10.1038/nm.2934

10.1086/508748

10.1086/428404

10.1038/nm.2316

10.1097/COH.0b013e32833d1e87

10.1086/422258

10.1128/CVI.00637-12

10.1128/CVI.00038-12

10.1016/j.vaccine.2011.08.098

10.1371/journal.pone.0013983

10.1016/0042-6822(92)90752-B

10.1084/jem.20071331

10.1038/nm.1949

10.1126/science.1207227

10.1016/j.jim.2008.11.012

10.1126/science.1178746

10.1126/science.1192819

10.1038/nature11544

10.1016/j.str.2010.06.010

10.1073/pnas.1004728107

10.1128/JVI.05086-11

10.1128/JVI.02419-10

10.1038/nm.1967

10.1038/nature10660

10.1371/journal.pone.0000984

10.1097/QAD.0b013e3283021a8c

10.1128/JVI.01061-08

10.1086/587993

10.1016/S0140-6736(08)61591-3

10.1038/79626

10.1099/0022-1317-83-1-75

10.1099/vir.0.19701-0

Jaoko W, 2008, Safety and immunogenicity of recombinant low dosage HIV‐1 A vaccine candidates vectored by plasmid pTHr DNA or modified vaccinia virus Ankara (MVA) in humans in East Africa, Virology, 26, 2788

10.4049/jimmunol.171.10.5611

10.1016/j.vaccine.2007.10.061

10.1097/QAD.0b013e32834ed9b2

10.1002/eji.201040344

10.1128/JVI.01779-12

10.1371/journal.ppat.0030157

10.1128/JVI.79.5.2956-2963.2005

10.1016/j.vaccine.2009.07.039

10.1093/bioinformatics/btn251

10.1038/nm1461

10.1038/nm.2089

10.1038/nm.2108

10.1111/j.1600-065X.2010.00980.x

10.1371/journal.pone.0021225

10.1016/j.vaccine.2011.05.025

10.1097/COH.0b013e32833cfe4c

10.1126/scitranslmed.3003155

10.1093/infdis/jir850

10.1126/scitranslmed.3002925

10.1128/JVI.75.23.11603-11613.2001

10.1016/j.vaccine.2009.10.145

10.1093/infdis/jis342

10.1128/JVI.02616-07

10.1128/JVI.02055-12

10.1128/JVI.02058-12

10.1128/JVI.00928-12

10.1128/JVI.00740-12

10.1093/infdis/jis285

10.1093/infdis/jis670

10.1093/infdis/jis671

Thông tin
Thông tin xuất bản

Immunological Reviews

Tập 254 Số 1

295-304

Thông tin tác giả